- Home
- EXFY vs FDMT Comparison
EXFY vs FDMT Comparison
Compare EXFY & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- FDMT
- Stock Information
- Founded
- EXFY 2008
- FDMT 2013
- Country
- EXFY United States
- FDMT United States
- Employees
- EXFY N/A
- FDMT N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- FDMT Health Care
- Exchange
- EXFY Nasdaq
- FDMT Nasdaq
- Market Cap
- EXFY 206.1M
- FDMT 207.1M
- IPO Year
- EXFY 2021
- FDMT 2020
- Fundamental
- Price
- EXFY $2.40
- FDMT $4.13
- Analyst Decision
- EXFY Strong Buy
- FDMT Buy
- Analyst Count
- EXFY 3
- FDMT 10
- Target Price
- EXFY $4.75
- FDMT $32.33
- AVG Volume (30 Days)
- EXFY 444.1K
- FDMT 449.2K
- Earning Date
- EXFY 08-07-2025
- FDMT 08-07-2025
- Dividend Yield
- EXFY N/A
- FDMT N/A
- EPS Growth
- EXFY N/A
- FDMT N/A
- EPS
- EXFY N/A
- FDMT N/A
- Revenue
- EXFY $141,775,000.00
- FDMT $23,000.00
- Revenue This Year
- EXFY $7.77
- FDMT $13,048.65
- Revenue Next Year
- EXFY $5.45
- FDMT N/A
- P/E Ratio
- EXFY N/A
- FDMT N/A
- Revenue Growth
- EXFY N/A
- FDMT N/A
- 52 Week Low
- EXFY $1.26
- FDMT $2.24
- 52 Week High
- EXFY $4.13
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- EXFY 51.05
- FDMT 54.45
- Support Level
- EXFY $2.19
- FDMT $4.21
- Resistance Level
- EXFY $2.33
- FDMT $4.62
- Average True Range (ATR)
- EXFY 0.11
- FDMT 0.30
- MACD
- EXFY 0.02
- FDMT -0.02
- Stochastic Oscillator
- EXFY 69.01
- FDMT 37.42
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.